Preimplantation Genetic Testing Market Strategy Guide: Unlocking Success in a High-Growth Sector

Preimplantation Genetic Testing Market Size

The global Preimplantation Genetic Testing (PGT) market was valued at USD 848.11 million in 2024 and is projected to grow from USD 905.87 million in 2025 to USD 1534.47 million by 2033, exhibiting a CAGR of 6.81% during the forecast period. PGT has become integral to Assisted Reproductive Technologies (ART), offering early detection of genetic abnormalities in embryos before implantation. The growth is primarily driven by rising infertility rates, increasing awareness of hereditary diseases, technological advancements in genetic screening (NGS, PCR), and the growing trend of delayed parenthood.

Market Opportunities

Expansion in Emerging Markets
Emerging economies such as India, China, Brazil, and the Middle East present untapped growth opportunities. Rising infertility rates, enhanced healthcare infrastructure, and government initiatives like India's National Health Mission have fueled demand for ART and PGT. Investments in AI-driven genetic diagnostics and affordable PGT solutions tailored to regional demographics further bolster this opportunity.

For instance, in October 2024, Manipal Fertility launched a genetic testing facility in Bangalore, leveraging next-generation sequencing (NGS) and AI-powered analysis tools to expand affordable services in India.

Current Market Trends

Integration of AI and Automation
The integration of Artificial Intelligence (AI) and automation is revolutionizing the PGT landscape by enhancing diagnostic precision and operational efficiency. AI-based platforms support embryologists in embryo selection, improving IVF success rates. Leading companies like CooperSurgical introduced AI-integrated systems in January 2025, enabling faster turnaround times, reduced costs, and better diagnostic outcomes.

Additionally, AI-assisted embryo imaging and automated sample preparation are standardizing procedures and reducing human error, further driving adoption across fertility clinics worldwide.

Market Challenges

Ethical and Regulatory Barriers
Despite technological advancements, the market faces challenges related to ethical debates surrounding embryo selection and the fear of “designer babies.” Regulatory landscapes differ globally—countries like India allow PGT only for disease prevention, prohibiting non-medical sex selection. These disparities create hurdles for global service delivery.

Moreover, the high cost of PGT procedures and inconsistent insurance coverage, especially in developing economies, limits accessibility and slows adoption.

Get Free Sample Report PDF @ https://straitsresearch.com/report/preimplantation-genetic-testing-market/request-sample

Regional Analysis

North America
North America dominates the PGT market due to advanced healthcare infrastructure, high IVF adoption rates, and favorable reimbursement frameworks. The U.S. leads with strong R&D investments and collaborations between fertility clinics and genetic testing providers like Natera and Illumina. Canada is steadily growing, supported by its publicly funded healthcare system and reproductive health R&D.

Europe
Europe represents a mature and heavily regulated market, led by the UK, Germany, and France. Regulatory bodies like HFEA and EMA ensure high testing standards. Government initiatives and cross-border fertility treatments fuel demand. Germany benefits from robust healthcare funding and innovation in medical genetics.

Asia-Pacific
The Asia-Pacific region is the fastest-growing market, driven by China, India, South Korea, and Japan. Relaxed family policies and healthcare modernization initiatives in China, alongside India’s growing fertility sector and increasing medical tourism, underpin rapid expansion. Advanced technologies and international collaborations further accelerate growth.

Middle East & Africa / LATAM
These regions are gradually adopting PGT, fueled by improvements in fertility infrastructure and rising awareness. Countries like the UAE, Saudi Arabia, and Brazil are making strides through public-private partnerships and healthcare reforms.

Segment Overview

By Procedure
Preimplantation Genetic Screening (PGS): Focuses on identifying chromosomal abnormalities to improve IVF success rates.

Preimplantation Genetic Diagnosis (PGD): Targets specific genetic mutations, preferred by couples with a family history of genetic disorders.

By Product
Reagents and Consumables: Dominates the segment, driven by the need for DNA amplification kits, sequencing reagents, and related consumables in PGT workflows.

Instruments: Includes genetic sequencers and diagnostic platforms.

Software: AI-powered data analytics tools for accurate interpretation and reporting.

By Technology
Next-Generation Sequencing (NGS): Leading technology due to its comprehensive genomic analysis capabilities.

Polymerase Chain Reaction (PCR): Essential for detecting specific mutations with high sensitivity.

Fluorescent In Situ Hybridisation (FISH): Used for chromosomal analysis.

Others: Emerging technologies complementing existing methods.

By Application
Chromosomal Abnormalities: Screening for aneuploidies and structural variations.

Aneuploidy Screening: Enhances implantation success by identifying embryos with normal chromosome numbers.

X-linked Diseases: Prevents transmission of sex-linked genetic disorders.

Embryo Testing: Comprehensive embryo health assessments.

Human Leukocyte Antigen (HLA) Typing: Assists in sibling donor matching.

Others: Additional niche genetic conditions.

By End-User
Hospitals: Integrated reproductive health services with in-house genetic labs.

Fertility Centres: Primary users, integrating PGT into IVF protocols.

Diagnostic Centres: Offer specialized genetic testing.

Research Centres and Academic Labs: Innovate and refine genetic testing technologies.

Buy Preimplantation Genetic Testing Market Research Report @ https://straitsresearch.com/buy-now/preimplantation-genetic-testing-market

Impact of Global Crises

Global crises such as COVID-19 and geopolitical conflicts initially disrupted IVF and PGT services. However, recovery has been strong, with delayed fertility treatments driving pent-up demand. Rising health awareness post-pandemic further accelerated adoption of preventive healthcare technologies like PGT.

Recent Developments

Illumina Inc. launched VeriSeq PGS 3.0 in November 2023, enhancing accuracy and efficiency.

CooperSurgical Inc. introduced AI-integrated PGT systems in January 2025, streamlining operations.

Invitae Corporation partnered with fertility clinics in March 2025 to integrate genetic counselling with PGT.

Leading Companies

1. Oxford Gene Technology
2. Thermo Fisher Scientific Inc.
3. SciGene Corporation
4. Agilent Technologies Inc.
5. PerkinElmer Inc.
6. Coopersurgical Inc.
7. Abbott Laboratories
8. Illumina Inc.
9. Natera Inc
10. Yikon Genomics

About Us

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

Contact Us

Phone: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)

Email: sales@straitsresearch.com